A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Official title

A Phase III, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Once-Daily Oral ASC30 in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (AURORA-1)

Study identification

NCT ID

NCT07743463

Recruitment status

Recruiting

Study type

Interventional

Phase

Phase 3

Lead sponsor

Ascletis Pharma (China) Co., Limited

Industry

Enrollment

3,003 participants

Conditions and interventions

Eligibility (public fields only)

Age range

18 Years and older

Sex

All

Healthy volunteers

Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date

Jul 31, 2026

Primary completion

Jun 30, 2028

Completion

Jun 30, 2028

Last update posted

Aug 13, 2026

2026 – 2028

United States locations

U.S. sites

67

U.S. states

25

U.S. cities

66

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 53 non-U.S. sites.

Recently updated Obesity trials

Other public records listing Obesity. Sorted by last update posted; newest first. Not a recommendation.

• NCT07752979: Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities Recruiting
• NCT07792226: ENLIGHT Trial: ESG With Fundal Mucosal Ablation Not yet recruiting
• NCT07783802: A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event Not yet recruiting
• NCT07684144: Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION) Recruiting
• NCT07554638: Incretin Therapies in Obesity-related HFpEF Recruiting
• NCT05921487: Time Restricted Eating to Mitigate Obesity in Veterans With Spinal Cord Injury Active, not recruiting

All Obesity trials →